• megha sahebrao jadhav
• Snehal Shantanu Zoman
• Kavita Laxman Warungase
• dr. Prashant Shivaji Malpure

Until lately, cancer treatment involved four primary kinds of treatment: surgery, radiotherapy, chemotherapy and targeted therapy. Over the earlier decade, immuno-oncology (IO) has emerged as a novel and critical method for managing cancer therapy through the stimulation of the body’s own immune system to kill cancer cells. This recently recognised technique of treating cancer is quickly developing, with many accelerated endorsement by the US Food and Drug Administration and European Medicines Agency in 2019. Immune checkpoint inhibitors, in particular, have had exceptional effectiveness across a wide range of cancers and are the most well-established therapeutic class of IO drugs to date. Biomarker testing for the programmed death-ligand 1 (PD-L1) checkpoint target has been created and is currently mandatory before therapy with pembrolizumab (Keytruda, Merck) when used for non-small-cell lung carcinoma, gastric cancer, head and neck squamous cell carcinoma and cervical cancer, just as before treatment with atezolizumab (Tecentriq, Roche) when used for urothelial carcinoma. However, the significance of PD-L1 expression for checkpoint inhibition therapy in other tumour types remains unclear. Combining IO drugs with conventional therapy has recently been studied, and patient outcomes have shown to be significantly improved. While IO agents are fast transforming the standard of treatment for cancer patients, there are still numerous obstacles to overcome in terms of managing their side effects and ensuring that healthcare systems, such as the NHS, can finance these expensive therapies. In addition to cancer vaccines and chimeric antigen receptor T-cell treatments, the IO pipeline contains chimeric antigen receptor T-cell therapies, both of which have their own set of toxicity and cost-effectiveness concerns.

cancer, tumours, immuno-oncology, immunotherapy, antitumour, immunosuppression, immunosurveillance

"REVIEW ON: IMMUNO-ONCOLOGY AGENTS FOR CANCER THERAPY ", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 2, page no.e548-e561, February-2022, Available :http://www.jetir.org/papers/JETIR2202470.pdf

"REVIEW ON: IMMUNO-ONCOLOGY AGENTS FOR CANCER THERAPY ", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 2, page no. ppe548-e561, February-2022, Available at : http://www.jetir.org/papers/JETIR2202470.pdf